An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB.

TitleAn oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB.
Publication TypeJournal Article
Year of Publication2010
AuthorsMin J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, Macconaill LE, Beroukhim R, Bronson RT, Ryeom S, Hahn WC, Loda M, Cichowski K
JournalNat Med
Volume16
Issue3
Pagination286-94
Date Published2010 Mar
ISSN1546-170X
KeywordsAnimals, Cell Line, Tumor, DNA-Binding Proteins, Enhancer of Zeste Homolog 2 Protein, Gene Expression Regulation, Neoplastic, Genes, ras, Genes, Tumor Suppressor, Humans, Male, Mice, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasm Transplantation, NF-kappa B, Oncogenes, Polycomb Repressive Complex 2, Prostatic Neoplasms, ras GTPase-Activating Proteins, Signal Transduction, Transcription Factors, Transcriptional Activation
Abstract

Metastasis is responsible for the majority of prostate cancer-related deaths; however, little is known about the molecular mechanisms that underlie this process. Here we identify an oncogene-tumor suppressor cascade that promotes prostate cancer growth and metastasis by coordinately activating the small GTPase Ras and nuclear factor-kappaB (NF-kappaB). Specifically, we show that loss of the Ras GTPase-activating protein (RasGAP) gene DAB2IP induces metastatic prostate cancer in an orthotopic mouse tumor model. Notably, DAB2IP functions as a signaling scaffold that coordinately regulates Ras and NF-kappaB through distinct domains to promote tumor growth and metastasis, respectively. DAB2IP is suppressed in human prostate cancer, where its expression inversely correlates with tumor grade and predicts prognosis. Moreover, we report that epigenetic silencing of DAB2IP is a key mechanism by which the polycomb-group protein histone-lysine N-methyltransferase EZH2 activates Ras and NF-kappaB and triggers metastasis. These studies define the mechanism by which two major pathways can be simultaneously activated in metastatic prostate cancer and establish EZH2 as a driver of metastasis.

DOI10.1038/nm.2100
Alternate JournalNat Med
PubMed ID20154697
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700